CAINasdaqServices-Medical LaboratoriesFiscal year ends December 31

Caris Life Sciences, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$30.71+0.15 (+0.49%)

Close on Oct 19, 2026

Market cap: $8.69B
P/E (TTM): –
Dividend yield: –

Caris Life Sciences, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Revenue	812	412	306
Research & Development	102	114	117
Selling, General & Admin	392	322	292
Selling & Marketing	168	153	143
General & Administrative	225	169	149
Advertising Expenses	3.60	1.20	0.60
Total Costs & Expenses	767	669	626
Operating Income	45	-257	-320
Interest Expense	57	50	32
Interest & Investment Income	16	7.12	11
Other Non-Operating Income	-113	-25	-22
Asset Impairment Charges	0	0	0
Pretax Income	-68	-282	-341
Income Tax Expense	0	0	0
Net Income	-68	-282	-341
Net Income to Common	-538	-378	-463
EPS (Basic)(per share)	-3.22	-10.66	-13.24
EPS (Diluted)(per share)	-3.22	-10.66	-13.24
Shares Outstanding (Basic, Weighted)(shares)	167	35	35
Shares Outstanding (Diluted, Weighted)(shares)	167	35	35
EBITDA	68	-208	-271

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: 15.5%
Net margin: 10.6%
Return on equity, FY2025: 7.1%

Financial strength

Current ratio: 5.53
Debt to equity: 0.66
Debt to assets: 32.0%
Cash to current liabilities: –

Valuation

P/E ratio: –
Price to sales: 8.78
Price to book: 14.68
Dividend yield: –